This technology is an approach to treat poly-ADP ribose polymerase inhibitor (PARPi) resistant tumors by targeting the FLT1/VEGFR1 signaling pathway.
Tumors with cancer cells deficient in homologous recombination-mediated DNA repair, such as BRCA-mutated breast cancers, may be treated with poly-ADP ribose polymerase inhibitors (PARPis). Various PARPis have been shown to be initially effective, but patients later develop resistance, leading to cancer recurrence. The identification of signaling pathways contributing to the development of PARPi resistance can suggest therapeutic vulnerabilities for resistant tumors and permit the use of combination therapies for increased efficacy.
This technology identifies a relationship between the FLT1/VEGRF1 signaling pathway and the development of PARPi resistance. PARPi-resistant breast tumors show increased FLT1 expression, which, when targeted with antagonists, resensitizes tumors to PARP inhibition. This technology highlights a potential therapeutic target for reversing PARPi resistance and can help identify therapeutic vulnerabilities for PARPi-resistant tumors, including BRCA-mutant breast cancers.
This technology has been validated in vivo.
Patent Pending
IR CU24001
Licensing Contact: Kristin Neuman